HDAX Therapeutics is pioneering next-gen small molecule therapeutics to transform patient outcomes in neuropathies, cardiometabolic diseases and beyond. By leveraging our unique molecular recognition technology, HDAX has engineered a novel 2-site binding mechanism to target the validated and attractive disease driver protein HDAC6, which overcomes critical shortcomings of current molecules such as weak binding, poor BBB penetration, off-target toxicities, and suboptimal PK profiles.

HDAX has a pipeline of central-acting molecules for neuromuscular indications (Chemotherapy-induced peripheral neuropathy – animal efficacy completed with full disease reversal and cognitive benefits observed, Charcot-Marie-Tooth) and peripheral-restricted molecules for cardiometabolic diseases (Heart failure with preserved ejection fraction, obesity).